Some new business models seem to take shape in the fluctuating space of capital markets. More and more mergers come to the benefit of end users, such as pharmaceutical companies that mix business with science. Teva Pharmaceuticals is such a case, getting set and ready to break through the unfamiliar ground of movement disorder treatment markets. This announcement has been made as a result of a merger between Teva and Auspex Pharmaceuticals, … [Read more...]
Vertex Pharmaceuticals Reviews Its Progress In the First Quarter of 2015
On April 29, the Boston-based American company Vertex Pharmaceuticals Inc. had a conference call in which the company's financial results in the first quarter of 2015 were reviewed. According to Jeff Leiden, 2015 is a very important year for Vertex Pharmaceuticals, which is the lead pharmaceutical company in the development of cystic fibrosis treatments. Cystic fibrosis is a disease which makes sticky mucus develop in the lungs and other … [Read more...]
Pfizer Pharmaceuticals and Noble ROI in Capital Markets
The healthcare sector is continuously changing and in the face of this widespread consolidation, countless pharmaceutical companies are losing the exclusivity on best-selling drugs. Of course, mergers and acquisitions are essential in such a volatile market and Pfizer pharmaceuticals seems to have already understood this. The gigantic pharma company has repeatedly left analysts and investors surprised with unusual acquisition picks. Pfizer … [Read more...]
Lack of Transparency Causes Big Image Losses for Big Pharma Companies
It’s not easy being a respected Big Pharma company nowadays. News travels fast if and when you come up with a new miracle drug meant to treat one of the millions of diseases out there. Then again, you also get a lot of praise and your profits are bigger which translates into shareholder satisfaction. You can prepare an informative documentary meant to explain how the drug works and what its benefits are. You gather doctors and medical experts … [Read more...]